



Synthesis of a near infrared-actuated phthalocyanine-lipid vesicle system for augmented photodynamic therapy

Nnamdi Nwahara^a, Muthumuni Managa^a, Mhlahli Stoffels^b, Jonathan Britton^a, Earl Prinsloo^b, Tebello Nyokong^{a,*}

^a Institute for Nanotechnology Innovation, Department of Chemistry, Rhodes University, Grahamstown 6140, South Africa

^b Biotechnology Innovation Centre, Rhodes University, Grahamstown 6140, South Africa

ARTICLE INFO

Keywords:

Hypoxia
Enhanced photodynamic therapy
Nanoparticles
Nanocatalysts
Liposomes
Phthalocyanines

ABSTRACT

The efficacy of photodynamic therapy (PDT) is often limited by the poor bio-distributive properties of conventional photosensitizers and the local hypoxic microenvironment that characterises most solid tumours. Herein, a novel in situ oxygenic lipid formulation for photodynamic therapy (PDT) is reported. Such a hybrid was synthesized by adsorbing bimetallic nanozyme MnO₂@PtNPs (NPs = nanoparticles) onto graphene quantum dots (GQDs) – zinc (II) phthalocyanine conjugates, followed by liposomal encapsulation, affording it enhanced water solubility. The MnO₂@PtNPs, which are shown to possess excellent catalase-like properties surpassing that of MnO₂ or PtNPs alone, serves to catalyze H₂O₂ to O₂, while the zinc (II) phthalocyanine (1) serves to transform the formed oxygen to generate cytotoxic singlet oxygen immediately. We show that by combining each function of the respective building blocks, the as-synthesized 1-GQDs-MnO₂@PtNPs-liposomes not only maintains the properties of oxygen supplementation through H₂O₂ catalysis but also displays cooperative properties for enhanced singlet oxygen production. Consequently, a remarkably improved PDT efficacy was observed for 1-GQDs-MnO₂@PtNPs-liposomes in both normoxia and hypoxia. These results demonstrate the potential applicability of such nanozyme constituted 1-GQDs-MnO₂@PtNPs-liposomes for achieving tumour treatment in hypoxic conditions by PDT.

1. Introduction

Growing research interest in photodynamic therapy (PDT), a non-invasive therapeutic modality for cancer, has continued as an alternative to more conventional modalities (such as chemotherapy and radiation). PDT's local light-controllable activation, as well as its tolerance to repeated doses [1–3], have been largely responsible for such sustained interest. In principle, the photosensitizer (PS), in its excited triplet state, transfers energy to molecular oxygen to produce reactive singlet oxygen (¹O₂), which is responsible for cancer cell death [4]. Most PSs that have been applied for PDT have been porphyrin derivatives, many of which are hydrophobic. As a result, they easily aggregate, leading to low tumour cell accumulation, and ultimately, poor clinical outcomes. Effective PSs delivery systems can help ensure a high degree of cellular uptake, where rapid PS release can alleviate the problem of the short half-life as well as limited diffusion distance of singlet oxygen [5,6].

Most tumour cells exist within a local hypoxic microenvironment, characterised by both a reduced oxygen supply and acidulated microenvironments [7,8]. Hypoxia is an essential consideration in any cancer-related therapy, particularly photodynamic therapy (PDT) since oxygen is a limiting factor. As a result, hypoxic cells are largely considered PDT resistant [9]. Thus, overcoming hypoxia by replenishing the tumour oxygen supply is recognized as vital to PDT success [10–12]. To this end, numerous reports have explored strategies to modulate tumour hypoxia. To date, two major pathways have been highlighted to overcome tumour hypoxia: oxygen-independent PDT (Type I PDT) [13, 14], and tumour oxygenation [15]. Although promising, oxygen-independent PDT does not alter the tumour microenvironment and as such, issues such as drug-resistant gene expression remain largely unresolved [15]. In contrast, tumour oxygenation has aroused considerable research interest owing to its ability to alter the tumour microenvironment, as well as attenuating resistance [16,17]. Traditional approaches such as extending tumour irradiation with low fluence rates, only work

* Corresponding author.

E-mail address: t.nyokong@ru.ac.za (T. Nyokong).

<https://doi.org/10.1016/j.synthmet.2021.116811>

Received 21 March 2021; Received in revised form 5 May 2021; Accepted 9 May 2021

Available online 20 May 2021

0379-6779/© 2021 Elsevier B.V. All rights reserved.